ERα positively regulated DNMT1 expression by binding to the gene promoter region in human breast cancer MCF-7 cells

Biochemical and Biophysical Research Communications

Volumn 427, Issue 1, 2012, Pages 47-53

  Shi, Jun Feng ^a   Li, Xing Jia ^a   Si, Xin Xin ^a   Li, An Di ^a   Ding, Hai Jian ^a   Han, Xiao ^a   Sun, Yu Jie ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; DNA methylation; DNMT1; ER ; Paclitaxel resistance

Indexed keywords

BETA ACTIN; DNA METHYLTRANSFERASE 1; ESTROGEN RECEPTOR ALPHA; PACLITAXEL;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN MCF 7; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; ENZYME INDUCTION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; PACLITAXEL; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC;

EID: 84867644007     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.08.144     Document Type: Article

References (38)

1. Szekely B., Szentmartoni G., Kulka J., Szasz A.M., Langmar Z., Dank M. Primary systemic therapy in breast cancer-an update for gynecologic oncologists. Eur. J. Gynaecol. Oncol. 2011, 32:636-641.
2. Lee J.H., Nan A. Combination drug delivery approaches in metastatic breast cancer. J. Drug. Deliv. 2012, 2012:915375.
3. Liu J., He C., Zhou K., Wang J., Kang J.X. Coptis extracts enhance the anticancer effect of estrogen receptor antagonists on human breast cancer cells. Biochem. Biophys. Res. Commun. 2009, 378:174-178.
4. Plaza-Menacho I., Morandi A., Robertson D., Pancholi S., Drury S., Dowsett M., Martin L.A., Isacke C.M. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene 2010, 29:4648-4657.
5. Barrios C.H., Sampaio C., Vinholes J., Caponero R. What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?. Ann. Oncol. 2009, 20:1157-1162.
6. Semilgazov V.F., Manikhas A.G., Semiglazov V.V., Bozhok A.A., Dashian G.A., Ivanov V.G., Paltuev R.M., Vasil'ev A.G., Shchedrin D.E., Ermachenkova A.M., Nikitina I.V., Pen'kov K.D., Bessonov A.A., Tabagua T.T., Kolar'kova V.V. Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer. Vopr. Onkol. 2011, 57:567-577.
7. Sui M., Zhang H., Fan W. The role of estrogen and estrogen receptors in chemoresistance. Curr. Med. Chem. 2011, 18:4674-4683.
8. Sui M., Huang Y., Park B.H., Davidson N.E., Fan W. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res. 2007, 67:5337-5344.
9. Tabuchi Y., Matsuoka J., Gunduz M., Imada T., Ono R., Ito M., Motoki T., Yamatsuji T., Shirakawa Y., Takaoka M., Haisa M., Tanaka N., Kurebayashi J., Jordan V.C., Naomoto Y. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int. J. Oncol. 2009, 34:313-319.
10. Barone I., Brusco L., Fuqua S.A. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin. Cancer Res. 2010, 16:2702-2708.
11. Massarweh S., Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr. Relat. Cancer 2006, 13(Suppl. 1):S15-24.
12. Arpino G., Wiechmann L., Osborne C.K., Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance. Endocr. Rev. 2008, 29:217-233.
13. Hayashi S.I., Eguchi H., Tanimoto K., Yoshida T., Omoto Y., Inoue A., Yoshida N., Yamaguchi Y. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr. Relat. Cancer 2003, 10:193-202.
14. Osborne C.K., Schiff R., Fuqua S.A., Shou J. Estrogen receptor: Current understanding of its activation and modulation. Clin. Cancer Res. 2001, 7:4338s-4342s.
15. discussion 4411s-4412s.
16. Ying W., Wang S., Shi J., Sun Y. ER-/ER+ breast cancer cell lines exhibited different resistance to paclitaxel through pulse selection. Med. Oncol. 2012, 29:495-502.
17. Boettcher M., Kischkel F., Hoheisel J.D. High-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistance. PLoS One 2010, 5:e11002.
18. Stone A., Valdes-Mora F., Gee J.M., Farrow L., McClelland R.A., Fiegl H., Dutkowski C., McCloy R.A., Sutherland R.L., Musgrove E.A., Nicholson R.I. Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. PLoS One 2012, 7:e40466.
19. Wilting R.H., Dannenberg J.H. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist. Updat. 2012, 15:21-38.
20. Segura-Pacheco B., Perez-Cardenas E., Taja-Chayeb L., Chavez-Blanco A., Revilla-Vazquez A., Benitez-Bribiesca L., Duenas-Gonzalez A. Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. J. Transl. Med. 2006, 4:32.
21. Goll M.G., Bestor T.H. Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem. 2005, 74:481-514.
22. Chedin F. The DNMT3 family of mammalian de novo DNA methyltransferases. Prog. Mol. Biol. Transl. Sci. 2011, 101:255-285.
23. Jurkowska R.Z., Jurkowski T.P., Jeltsch A. Structure and function of mammalian DNA methyltransferases. Chembiochem 2011, 12:206-222.
24. Svedruzic Z.M. Dnmt1 structure and function. Prog. Mol. Biol. Transl. Sci. 2011, 101:221-254.
25. Walton E.L., Francastel C., Velasco G. Maintenance of DNA methylation: Dnmt3b joins the dance. Epigenetics 2012, 6.
26. Cui M., Wen Z., Yang Z., Chen J., Wang F. Estrogen regulates DNA methyltransferase 3B expression in Ishikawa endometrial adenocarcinoma cells. Mol. Biol. Rep. 2009, 36:2201-2207.
27. Zhao Z., Fan L., Frick K.M. Epigenetic alterations regulate estradiol-induced enhancement of memory consolidation. Proc. Natl. Acad. Sci. USA 2010, 107:5605-5610.
28. Gravina G.L., Marampon F., Piccolella M., Motta M., Ventura L., Pomante R., Popov V.M., Zani B.M., Pestell R.G., Tombolini V., Jannini E.A., Festuccia C. Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models. Endocrinology 2011, 152:4550-4561.
29. Kawakami K., Matsunoki A., Kaneko M., Saito K., Watanabe G., Minamoto T. Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer. Cancer Sci. 2011, 102:166-174.
30. Roman-Gomez J., Jimenez-Velasco A., Agirre X., Cervantes F., Sanchez J., Garate L., Barrios M., Castillejo J.A., Navarro G., Colomer D., Prosper F., Heiniger A., Torres A. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 2005, 24:7213-7223.
31. Zeller C., Dai W., Steele N.L., Siddiq A., Walley A.J., Wilhelm-Benartzi C.S., Rizzo S., van der Zee A., Plumb J.A., Brown R. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 2012.
32. Zhang X., Li W., Li H., Ma Y., He G., Tan G. Genomic methylation profiling combined with gene expression microarray reveals the aberrant methylation mechanism involved in nasopharyngeal carcinoma taxol resistance. Anticancer Drugs 2012, 23:856-864.
33. Qiu Y.Y., Mirkin B.L., Dwivedi R.S. Differential expression of DNA-methyltransferases in drug resistant murine neuroblastoma cells. Cancer Detect. Prev. 2002, 26:444-453.
34. Qiu Y.Y., Mirkin B.L., Dwivedi R.S. Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells. Cancer Detect. Prev. 2005, 29:456-463.
35. Beyrouthy M.J., Garner K.M., Hever M.P., Freemantle S.J., Eastman A., Dmitrovsky E., Spinella M.J. High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. Cancer Res. 2009, 69:9360-9366.
36. Ostler K.R., Yang Q., Looney T.J., Zhang L., Vasanthakumar A., Tian Y., Kocherginsky M., Raimondi S.L., Demaio J.G., Salwen H.R., Gu S., Chlenski A., Naranjo A., Gill A., Peddinti R., Lahn B.T., Cohn S.L., Godley L.A. Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation and alters DNA methylation in human neuroblastoma. Cancer Res. 2012.
37. Sandhu R., Rivenbark A.G., Coleman W.B. Enhancement of chemotherapeutic efficacy in hypermethylator breast cancer cells through targeted and pharmacologic inhibition of DNMT3b. Breast Cancer Res. Treat. 2012, 131:385-399.
38. Qin W., Leonhardt H., Pichler G. Regulation of DNA methyltransferase 1 by interactions and modifications. Nucleus 2011, 2:392-402.